Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIVATE: BIA 28-6156 in GBA1-variant Parkinson’s Disease
2022-501783-18-00Phase 2Completed
- Sponsor
- BIAL
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing BIA 28-6156 with Placebo (2 arms). Primary endpoint: Time to clinically meaningful progression in motor aspects of experiences of daily living. Started Jul 2023; status: completed.
02
Drugs
pariceract
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2022-501783-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501783-18-00.